Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* history of blepharitis and meet qualifying criteria for an acute exacerbation of blepharitis in both eyes at Screening and Baseline/Day 1 Visits~* have a qualifying best-corrected visual acuity~Exclusion Criteria:~* abnormality of the eyelids or lashes (other than blepharitis), or previous eyelid surgery~* IOP \> 21 mmHg at Screening or Baseline/Day 1 Visits~* use of steroids in the past 30 days or retinoids in the past 12 months~* uncontrolled systemic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NCX 4251 QD (Type: EXPERIMENTAL): NCX 4251 Ophthalmic Suspension, 0.1% once daily for 14 days
- Placebo QD (Type: PLACEBO_COMPARATOR): Placebo once daily for 14 days
- NCX 4251 BID (Type: EXPERIMENTAL): NCX 4251 Ophthalmic Suspension, 0.1% twice daily for 14 days
- Placebo BID (Type: PLACEBO_COMPARATOR): Placebo twice daily for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).